Free Trial

Trading of Cyclacel Pharmaceuticals was halted at 11:38 AM EST due to "LULD pause".

NASDAQ:CYCC

Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

Cyclacel Pharmaceuticals logo
$13.07 +4.84 (+58.81%)
Closing price 04:00 PM Eastern
Extended Trading
$12.16 -0.92 (-7.00%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)

Key Stats

Today's Range
$8.00
$18.00
50-Day Range
$0.23
$53.85
52-Week Range
$3.08
$597.60
Volume
22.29 million shs
Average Volume
419,617 shs
Market Capitalization
$20.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Cyclacel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
25th Percentile Overall Score

CYCC MarketRank™: 

Cyclacel Pharmaceuticals scored higher than 25% of companies evaluated by MarketBeat, and ranked 828th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cyclacel Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cyclacel Pharmaceuticals is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Cyclacel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.08% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently decreased by 99.78%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cyclacel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Cyclacel Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.08% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently decreased by 99.78%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cyclacel Pharmaceuticals has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 26 news articles for Cyclacel Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    14 people have searched for CYCC on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    51.20% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

  • Read more about Cyclacel Pharmaceuticals' insider trading history.
Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CYCC Stock News Headlines

Critical AI announcement set to ignite AI 2.0
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?
Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday?
Cyclacel Pharmaceuticals, Inc. (CYCCP) - Yahoo Finance
See More Headlines

CYCC Stock Analysis - Frequently Asked Questions

Cyclacel Pharmaceuticals' stock was trading at $90.24 at the start of the year. Since then, CYCC stock has decreased by 85.5% and is now trading at $13.07.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its quarterly earnings results on Wednesday, April, 2nd. The biotechnology company reported ($79.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($69.60) by $9.60. The biotechnology company earned $0.01 million during the quarter, compared to analyst estimates of $0.01 million.

Shares of Cyclacel Pharmaceuticals reverse split on Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET).

Company Calendar

Last Earnings
4/02/2025
Record date for 5/1 Dividend
4/29/2025
Ex-Dividend for 5/1 Dividend
4/29/2025
Dividend Payable
5/01/2025
Today
7/18/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYCC
CIK
1130166
Employees
14
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($839.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.21 million
Net Margins
N/A
Pretax Margin
-55,535.71%
Return on Equity
-3,648.09%
Return on Assets
-155.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.60
Quick Ratio
5.60

Sales & Book Value

Annual Sales
$40 thousand
Price / Sales
516.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($58.87) per share
Price / Book
-0.22

Miscellaneous

Outstanding Shares
1,580,000
Free Float
773,000
Market Cap
$20.65 million
Optionable
Optionable
Beta
0.03

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:CYCC) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners